Sign In
Buy GLPG
$27.38
+0.0650 (+0.238%)
At Close: Jun 03, 2026
Galapagos shares down after announcing clinical-trial miss for Crohn's disease
08:35am, Thursday, 09'th Feb 2023
U.S.-listed shares of Galapagos GLPG, +0.41% were down 8.9% in premarket trading on Thursday, the day after the company said an experimental treatment for Crohn's disease missed the primary endpoints
Galapagos to present at 41th Annual J.P. Morgan Healthcare Conference
04:01pm, Tuesday, 03'rd Jan 2023
Mechelen, Belgium; 3 January 202 3 , 22.01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) will participate in the 4 1t h Annual J.P. Morgan Healthcare Conference on January 9 -1 2 , 202 3 .
Galapagos: Slow Transformation, But Led By An Expert
12:54am, Saturday, 31'st Dec 2022
GLPG is setting to transform its business after a slew of failures. The new CEO is a global expert at this, and I don't see him failing.
3 Beaten-Down Drug Stocks Poised for a Turnaround in 2023
11:36am, Wednesday, 28'th Dec 2022
Here we present three drug and biotech stocks, VIR, GLPG and PCRX, which took a beating in 2022 but have upside potential for 2023, despite an uncertain macro environment.
Does Galapagos NV (GLPG) Have the Potential to Rally 34% as Wall Street Analysts Expect?
02:55pm, Friday, 16'th Dec 2022 Zacks Investment Research
The average of price targets set by Wall Street analysts indicates a potential upside of 34.4% in Galapagos NV (GLPG). While the effectiveness of this highly sought-after metric is questionable, the p
Galapagos and CellPoint presented encouraging initial data at ASH 2022 for GLPG5101, a CD19 CAR-T candidate manufactured at point-of-care
06:00am, Tuesday, 13'th Dec 2022 GlobeNewswire Inc.
Mechelen, Belgium; 13 December 2022, 7.00 CET; Galapagos NV (Euronext & NASDAQ: GLPG) and CellPoint (a Galapagos company) today presented encouraging initial data from the ongoing ATALANTA-1 Phase 1/2
Galapagos en CellPoint hebben op ASH 2022 bemoedigende eerste data gepresenteerd van GLPG5101, een CD19 CAR-T-kandidaat die point-of-care wordt geproduceerd
06:00am, Tuesday, 13'th Dec 2022 GlobeNewswire Inc.
Mechelen, België; 13 december 2022, 7.00 CET; Galapagos NV (Euronext & NASDAQ: GLPG) en CellPoint (een Galapagos bedrijf) hebben vandaag op het 64th Annual American Society of Hematology (ASH) Congre
Down 5.9% in 4 Weeks, Here's Why Galapagos NV (GLPG) Looks Ripe for a Turnaround
02:35pm, Thursday, 08'th Dec 2022 Zacks Investment Research
Galapagos NV (GLPG) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estima
Down 5.9% in 4 Weeks, Here's Why Galapagos NV (GLPG) Looks Ripe for a Turnaround
11:17am, Thursday, 08'th Dec 2022
Galapagos NV (GLPG) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estima
Galapagos kondigt aan dat het CHMP de aanbeveling van het PRAC voor Jyseleca® heeft overgenomen na een uitgebreide veiligheidsbeoordeling van alle JAK-remmers
12:15pm, Friday, 11'th Nov 2022 GlobeNewswire Inc.
Mechelen, België; 11 november 2022, 13.15 CET; Galapagos NV (Euronext & NASDAQ: GLPG) heeft vandaag aangekondigd dat het Comité voor geneesmiddelen voor menselijk gebruik (CHMP), het wetenschappeli
Galapagos announces CHMP adoption of PRAC’s recommendation for Jyseleca® following extensive safety review of all JAK inhibitors
12:15pm, Friday, 11'th Nov 2022 GlobeNewswire Inc.
Mechelen, Belgium; 11 November 2022, 13.15 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee
Galapagos to present encouraging initial data from FILOSOPHY real-world arthritis study at ACR Convergence 2022
04:01pm, Tuesday, 08'th Nov 2022
Mechelen, Belgium; 8 November 2022, 22.01 CET, Galapagos NV (Euronext & NASDAQ: GLPG) will present new data on filgotinib at the American College of Rheumatology ( ACR ) Co n vergence 2022 meeting tak
Benzinga's Top Ratings Upgrades, Downgrades For November 7, 2022
02:25pm, Monday, 07'th Nov 2022 Benzinga
Upgrades
Guggenheim upgraded the previous rating for Okta Inc (NASDAQ:OKTA) from Neutral to Buy. For the second quarter, Okta had an EPS of $0.10, compared to year-ago quarter EPS of $0.11. The curren
Galapagos presenteert stappenplan voor pijplijn- en commerciële groei op haar R&D-dag 2022
08:01pm, Friday, 04'th Nov 2022 GlobeNewswire Inc.
Webcast replay beschikbaar op www.glpg.com
Galapagos presents roadmap for pipeline and commercial growth at its R&D Day 2022
08:01pm, Friday, 04'th Nov 2022 GlobeNewswire Inc.
Webcast replay available at www.glpg.com
